Can a tiny beacon make prostate radiation safer?

NCT ID NCT03254420

Ongoing Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a device called Calypso, which tracks the prostate's position in real time during radiation, can reduce long-term side effects compared to standard image-guided radiation. 74 men with low- or intermediate-risk prostate cancer took part. The goal is to see if more precise targeting leads to fewer bowel and bladder problems after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Calypso beacon implant and moderate hypofractionation radiotherapy
What this could lead to: If successful, this could show that using the Calypso tracking system reduces long-term side effects from radiation for prostate cancer.
What could go wrong: This is a small, early-phase study (74 patients) and may not prove a clear benefit. The technology adds an extra implant procedure, which carries its own risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Institut regional du Cancer - Val d Aurelle

Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.